These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34028178)

  • 1. Targeting the glycans: A paradigm for host-targeted and COVID-19 drug design.
    Pourrajab F
    J Cell Mol Med; 2021 May; 25(13):5842-56. PubMed ID: 34028178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
    Kim CH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor.
    Nguyen KV
    Nucleosides Nucleotides Nucleic Acids; 2021; 40(6):665-706. PubMed ID: 33982646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restriction of Human Cytomegalovirus Infection by Galectin-9.
    Machala EA; Avdic S; Stern L; Zajonc DM; Benedict CA; Blyth E; Gottlieb DJ; Abendroth A; McSharry BP; Slobedman B
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30487283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Containing the spread of COVID-19 virus facing to its high mutation rate: approach to intervention using a nonspecific way of blocking its entry into the cells.
    Nguyen KV
    Nucleosides Nucleotides Nucleic Acids; 2022; 41(8):778-814. PubMed ID: 35532338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legume Lectins with Different Specificities as Potential Glycan Probes for Pathogenic Enveloped Viruses.
    Barre A; Van Damme EJM; Klonjkowski B; Simplicien M; Sudor J; Benoist H; Rougé P
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms.
    Davicino RC; Eliçabe RJ; Di Genaro MS; Rabinovich GA
    Int Immunopharmacol; 2011 Oct; 11(10):1457-63. PubMed ID: 21600310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
    Nandi S; Roy H; Gummadi A; Saxena AK
    Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.
    Galili U
    Med Res Arch; 2021 Jul; 9(7):. PubMed ID: 34853815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2.
    Nguyen K; Chakraborty S; Mansbach RA; Korber B; Gnanakaran S
    Viruses; 2021 May; 13(5):. PubMed ID: 34067878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
    Galili U
    Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as "Achilles' Heel" of Viruses Contributing to Anti-Viral Immune Protection.
    Galili U
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens.
    Stowell SR; Arthur CM; Mehta P; Slanina KA; Blixt O; Leffler H; Smith DF; Cummings RD
    J Biol Chem; 2008 Apr; 283(15):10109-23. PubMed ID: 18216021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence and Re-emergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target.
    Ahmad F; Kamal MA; Tekwani BL
    Curr Pharm Des; 2021; 27(33):3566-3576. PubMed ID: 33327904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.